At Massive Bio, we are at the forefront of revolutionizing oncology through the power of artificial intelligence. Our groundbreaking platform is engineered to dismantle the barriers that have long hindered patient access to cutting-edge cancer treatments and clinical trials. Through our advanced, AI-driven technology, we are creating a new paradigm in cancer care, one that is patient-centric, data-driven, and globally accessible. We are committed to empowering every cancer patient, regardless of their location or financial situation, with the ability to connect with the most promising clinical trials and personalized treatment options available. Our mission is to accelerate the pace of cancer research and drug development by providing pharmaceutical companies and contract research organizations with an unparalleled, tech-enabled solution for patient identification, pre-screening, and enrollment.
Our innovative approach integrates a sophisticated AI platform with comprehensive, concierge-level services, addressing critical friction points throughout the clinical trial enrollment process. By leveraging real-world data and advanced analytics, we can rapidly and accurately match patients with trials that align with their unique genomic and clinical profiles. This not only enhances the efficiency of clinical trials but also fosters greater health equity by extending the reach of novel therapies to underserved communities. We collaborate with a vast network of top cancer centers, pharmaceutical leaders, and patient advocacy groups to create a unified ecosystem dedicated to advancing cancer treatment. Our work has been recognized by the National Cancer Institute, and we are proud to be a part of the White House Cancer Moonshot initiative, further solidifying our commitment to transforming the future of oncology and bringing hope to millions of patients worldwide.
United States only
CA and US only
